Boston Scientific (BSX) is under close watch after a series of voluntary Class II device recalls affecting FARADRIVE steerable sheaths and FARASTAR pulsed field ablation generators used in cardiac and vascular procedures worldwide.

The Boston Scientific share price has climbed in the last month, with a 30 day share price return of 10.14% and a 7 day gain of 5.52%. However, momentum has faded over the past quarter, with a 90 day share price return that declined 7.61% and a year to date share price return that declined 47.94%. Over a longer horizon, total shareholder return is mixed, with a 1 year total shareholder return that declined 52.19% but a 5 year total shareholder return of 11.23%, as investors weigh recent voluntary recalls against the latest earnings update and revised guidance.

If safety issues in cardiac devices have your attention, it can be useful to see how other healthcare focused AI opportunities are priced and growing via the Simply Wall St screener for 43 healthcare AI stocks

The sharp pullback this year, along with a recent bounce, leaves Boston Scientific at an awkward midpoint between concern over recalls and confidence in its earnings and guidance. How far does the current share price reflect either side of that story?

Most Popular Narrative: 31.8% Undervalued

Compared with the last close at $49.31, the most followed Boston Scientific narrative points to a fair value of $72.25, which is a sizeable gap that analysts tie to long term growth, margins and capital allocation plans.

Investment in proprietary, high-margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.

Read the complete narrative. Read the complete narrative.

If you want to understand why this valuation is higher than where Boston Scientific trades today, focus on the interplay of projected earnings growth, future profitability and the earnings multiple that analysts believe the company can support. The narrative links those three elements into a single path for fair value. The interesting part is how much of that path depends on margin strength rather than very fast revenue growth.

Result: Fair Value of $72.25 (UNDERVALUED)

However, the Boston Scientific story can change quickly if Watchman growth continues to reset, or if regulatory and reimbursement setbacks pressure margins and earnings expectations.

Next Steps

With Boston Scientific sitting between concern and optimism, now is a good time to review the full picture yourself and decide where you stand. To weigh up both the potential upsides and the key issues that investors are watching, start by checking the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Boston Scientific?

Do not stop with Boston Scientific. Use the tools at your fingertips to compare different kinds of opportunities and sharpen how you build your portfolio.

• Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations using the 52 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by reviewing companies with resilient finances through the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for off-the-radar opportunities with solid metrics by checking the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.